What monitoring does Cosentyx (secukinumab) require?
Cosentyx monitoring centers on safety checks before and during treatment, with added attention if you have a history of infections or inflammatory bowel disease (IBD).
Your clinician typically monitors for infections because IL-17 blockade can increase risk of infection. Patients are also checked for signs of active infection and are advised to report fever, cough, or other infection symptoms promptly.
Cosentyx can also worsen or trigger IBD activity in some people, so clinicians monitor for new or worsening GI symptoms such as persistent diarrhea, abdominal pain, or blood/mucus in stool.
Routine lab monitoring is not typically as frequent as for some other biologics, but your prescriber may order labs based on your age, comorbidities, and prior treatment history.
What tests are needed before starting Cosentyx?
Before the first dose, clinicians commonly evaluate:
- Infection history and current infection status (you typically should not start if you have an active infection).
- Screening relevant to tuberculosis (TB) and hepatitis risk, depending on local practice and your medical history.
- Baseline symptom review for IBD (if you have Crohn’s disease or ulcerative colitis), because GI monitoring is important once treatment starts.
If your clinician uses TB/hepatitis screening at your site, those results usually guide whether therapy can start and whether you need treatment first.
Does Cosentyx require TB or hepatitis screening?
Many biologics used for autoimmune diseases require TB screening before initiation, and this is also standard for IL-17 inhibitors in routine practice. Hepatitis screening may also be done depending on risk factors and local protocols.
The exact tests and timing can vary by country and clinic, but the key point is that your prescriber checks for latent or active infections before starting, then continues to watch for infections during treatment.
How often will I need follow-up while on Cosentyx?
Follow-up frequency depends on why you’re taking Cosentyx and how stable your disease is. Clinicians generally:
- Reassess symptoms and adverse effects at each visit.
- Monitor for infection signs between visits.
- Review for any GI changes that could suggest IBD flare.
There is no single universal schedule, but ongoing clinical assessment is expected throughout therapy.
What side effects should trigger urgent monitoring?
Contact your clinician promptly if you develop:
- Signs of infection (fever, chills, persistent cough, shortness of breath, painful urination).
- New or worsening bowel symptoms that could indicate IBD flare (especially persistent diarrhea, abdominal pain, blood in stool).
- Any allergic-type reactions after dosing.
Do monitoring requirements differ by indication (psoriasis vs psoriatic arthritis vs ankylosing spondylitis)?
The safety monitoring themes are the same (infection and IBD-related symptom monitoring), but the clinical follow-up focus can differ:
- Psoriasis: assess skin plaque control and safety symptoms.
- Psoriatic arthritis/ankylosing spondylitis: monitor joint symptoms, function, and infection risk.
- IBD history: closer attention to GI symptoms is especially important.
What should I ask my prescriber to confirm?
Since monitoring varies by your risk factors and country, it helps to confirm:
- Whether you’ve had TB testing and whether hepatitis screening is planned.
- What lab work (if any) you need and how often.
- What specific infection symptoms should prompt you to hold a dose or seek care.
- How your clinic wants IBD symptoms reported and when to stop or pause therapy.
Source
No sources were provided with your question, and I don’t have access to a Cosentyx-specific monitoring guideline from DrugPatentWatch.com in the information given here. If you share your country/indication (psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis) and whether you have any history of TB/hepatitis/IBD, I can tailor the monitoring questions more precisely.